Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gerald LaChance"'
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0147007 (2016)
BACKGROUND:Hepatitis C virus infection is a global health problem. New direct-acting antiviral agents have been recently approved. However, due to their high cost and some genotypes remaining difficult to treat, interferon-based therapy with pegylate
Externí odkaz:
https://doaj.org/article/9a0a8779013640aa91255a56770d3cd2
Autor:
Kanti Pabbaraju, Matthew A. Croxen, Holly A. Saffran, Kevin Crawford, Michael Logan, Gerald LaChance, Darren Hockman, John Lok Man Law, D. Lorne Tyrrell, Abdolamir Landi, Janelle Johnson, Graham Tipples, Raelynn Brassard, Justin Shields, Eve Hobart, Michael Houghton, M. Joanne Lemieux, Michael A. Joyce, Elena Arutyunova
Publikováno v:
Vaccine
SARS-CoV-2 is the etiological agent of COVID19. There are currently several licensed vaccines approved for human use and most of them are targeting the spike protein (or virion) in the virion envelope to induce protective immunity. Recently, variants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e103c5c330664243455b4cc9fc1daec9
https://doi.org/10.1016/j.vaccine.2021.08.081
https://doi.org/10.1016/j.vaccine.2021.08.081
Autor:
Joseph Marcotrigiano, John Lok Man Law, Amir Landi, Janelle Johnson, Chao Chen, Juthika Kundu, Steven K. H. Foung, Lorne Tyrrell, Michael Logan, Lesley Baldwin, Darren Hockman, Gerald LaChance, Michael Houghton, Anita Dahiya, Mansun Law, Kevin Crawford, Jason Wong
Publikováno v:
Journal of Virology. 91
A recombinant strain HCV1 (hepatitis C virus [HCV] genotype 1a) gpE1/gpE2 (E1E2) vaccine candidate was previously shown by our group to protect chimpanzees and generate broad cross-neutralizing antibodies in animals and humans. In addition, recent in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3733f71ce0bafd2e6bea86c484af1a6
https://doi.org/10.1128/jvi.01552-16
https://doi.org/10.1128/jvi.01552-16
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 1, p e0147007 (2016)
PLoS ONE, Vol 11, Iss 1, p e0147007 (2016)
Background Hepatitis C virus infection is a global health problem. New direct-acting antiviral agents have been recently approved. However, due to their high cost and some genotypes remaining difficult to treat, interferon-based therapy with pegylate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf8846796a76274d0689a463e3ca6e11
https://doi.org/10.1371/journal.pone.0147007
https://doi.org/10.1371/journal.pone.0147007
Autor:
Michael Mantler, James Willis, Gerald Lachance, Bruno A. R. Vrebos, Karl-Eugen Mauser, Naoki Kawahara, Richard M. Rousseau, Peter N. Brouwer
Publikováno v:
Handbook of Practical X-Ray Fluorescence Analysis ISBN: 9783540286035
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3561c4f31ff3452b84e858cccbf5789
https://doi.org/10.1007/978-3-540-36722-2_5
https://doi.org/10.1007/978-3-540-36722-2_5
